Cd4 - CD4 antigen Gene
Also Known as L3T4; Ly-4
Species: Mus musculus
Gene Type: protein coding
Gene ID: 12504
Summary
Predicted to enable several functions, including interleukin-16 binding activity; interleukin-16 receptor activity; and protein homodimerization activity. Involved in helper T cell enhancement of adaptive immune response. Acts upstream of or within several processes, including defense response to Gram-negative bacterium; positive regulation of calcium-mediated signaling; and positive regulation of peptidyl-tyrosine phosphorylation. Located in endoplasmic reticulum; external side of plasma membrane; and membrane raft. Is expressed in several structures, including alimentary system; brain; genitourinary system; hemolymphoid system; and liver and biliary system. Used to study type 1 diabetes mellitus. Human ortholog(s) of this gene implicated in immunodeficiency 79. Orthologous to human CD4 (CD4 molecule). [provided by Alliance of Genome Resources, Apr 2022]
Cd4 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_013488.3 | NP_038516.1 | T-cell surface glycoprotein CD4 precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables protein binding |
IPI
IPI: Inferred from physical interaction
|
7486703 | MGI |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
8612131 | MGI |
| located in endoplasmic reticulum lumen |
IDA
IDA: Inferred from direct assay
|
16223484 | MGI |
| located in endoplasmic reticulum membrane |
IDA
IDA: Inferred from direct assay
|
16223484 | MGI |
| located in external side of plasma membrane |
IDA
IDA: Inferred from direct assay
|
7477352 | MGI |
| located in membrane raft |
IDA
IDA: Inferred from direct assay
|
15128768 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
3262426 | MGI |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
T-cell surface glycoprotein CD4 |
|
Recombinant Cd4 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P72904 | CD4 Protein, Mouse (HEK293, His) | P06332-1/NP_038516.1 (K27-T394) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P77517 | CD4 Protein, Mouse (Biotinylated, HEK293, His-Avi) | NP_038516.1 (K27-T394) | ≥ 95%, as determined by reducing SDS-PAGE. |
Cd4 Antibodies
| Cat. No. | Product Name | Application | Reactivity |
|---|---|---|---|
| HY-P83756 | CD4 Antibody (YA3557) | WB, IHC-P, ICC/IF, mIHC | Mouse |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0689A | Indinavir sulfate | 99.97% | Yes | |
| HY-B0426A | Olopatadine hydrochloride | 99.83% | Unkown | |
| HY-15440A | Fostemsavir | Inhibitor | 99.69% | Unkown |
| HY-B0689 | Indinavir | 99.96% | Yes | |
| HY-15440B | Fostemsavir Tris | Inhibitor | 99.78% | Unkown |
| HY-W062109 | Olopatadine | 98.94% | Unkown | |
| HY-135432 | Etrasimod arginine | Modulator | 99.86% | Unkown |
| HY-B0426AR | Olopatadine hydrochloride (Standard) | / | Unkown | |
| HY-B0689B | Indinavir sulfate ethanolate | / | Unkown |
Inhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99222 | Teplizumab | 99.73% | Unkown | |
| HY-108831 | Natalizumab | Inhibitor | 99.10% | Unkown |
| HY-P99028 | Ibalizumab | Inhibitor | 99.74% | Unkown |
Clinical Phase
Bioactive Molecules
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-105037 | Forigerimod | Inhibitor | / | Phase 3 |
| HY-148511 | Vidutolimod | 93.85% | Phase 3 | |
| HY-13644 | Gusperimus | / | Phase 3 | |
| HY-148808 | Zelasudil | Inhibitor | 99.48% | Phase 2 |
| HY-14135 | BMS 488043 | Inhibitor | / | Phase 2 |
| HY-15440 | Temsavir | Inhibitor | 98.70% | Phase 1 |
| HY-P0272 | Peptide T | Inhibitor | 98.68% | Phase 1 |
| HY-139780 | JNJ-61803534 | Inhibitor | 99.84% | Phase 1 |
Inhibitory Antibodies
(19)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99266 | Zanolimumab | 99.33% | Phase 3 | |
| HY-P9998 | Semzuvolimab | Inhibitor | 97% | Phase 3 |
| HY-P991336 | Ordastobart | Agonist | 98% | Phase 3 |
| HY-P991214 | Tucotuzumab celmoleukin | 98.797% | Phase 3 | |
| HY-P9997 | Rosnilimab | Agonist | 99.19% | Phase 2 |
| HY-P99159 | Ivuxolimab | Activator | ≥99.0% | Phase 2 |
| HY-P99908 | Efineptakin alfa | Activator | 99.70% | Phase 2 |
| HY-P991069 | VRC-01 | Inhibitor | 99.805% | Phase 2 |
| HY-P990742 | Givastomig | Inhibitor | 98.556% | Phase 2 |
| HY-P990068 | Perenostobart | Inhibitor | 97.00% | Phase 2 |
| HY-P991424 | GSK2618960 | Inhibitor | 95.66% | Phase 2 |
| HY-P991246 | VRC01LS | Inhibitor | 98.78% | Phase 2 |
| HY-P99809 | Quavonlimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P99607 | Clenoliximab | Inhibitor | / | Phase 2 |
| HY-P99911 | Efizonerimod alfa | Agonist | 98.57% | Phase 1 |
| HY-P991307 | BND-35 | / | Phase 1 | |
| HY-P991436 | DF6002 | Activator | / | Phase 1 |
| HY-P991643 | MTRX1011A | Inhibitor | / | Phase 1 |
| HY-P991655 | AGS-009 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(150)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-150741C | ODN 2216 sodium | Agonist | 98.57% | Unkown |
| HY-P3719 | MOG(35-55) amide, mouse, rat | 99.88% | Unkown | |
| HY-110382 | Cyclic-di-GMP disodium | Activator | 98.78% | Unkown |
| HY-150741 | ODN 2216 | 98.57% | Unkown | |
| HY-126675A | AS2863619 | 98.02% | Unkown | |
| HY-143712 | Allolithocholic acid | 99.69% | Unkown | |
| HY-P2560 | LCMV GP (61-80) | 99.80% | Unkown | |
| HY-15898 | Y-320 | 99.03% | Unkown | |
| HY-120427 | Cosalane | Antagonist | 99.78% | Unkown |
| HY-107780B | Cyclic-di-GMP diammonium | Activator | 99.07% | Unkown |
| HY-134809 | Cyclotriazadisulfonamide | Inhibitor | 98.45% | Unkown |
| HY-P1684 | Peptide P60 | Inhibitor | 98.39% | Unkown |
| HY-P1066 | Apelin-17(human, bovine) | 98.71% | Unkown | |
| HY-Y0788 | Indoline | 99.89% | Unkown | |
| HY-160267 | iPAF1C | 99.59% | Unkown | |
| HY-164426 | HEI3090 | Activator | 99.00% | Unkown |
| HY-P1064 | Apelin-36(human) | 98.01% | Unkown | |
| HY-W181026 | KLF10-IN-1 | 99.84% | Unkown | |
| HY-108136A | Bisindolylmaleimide X hydrochloride | 98.90% | Unkown | |
| HY-124750 | NecroX-7 | Inhibitor | 99.69% | Unkown |
| HY-126675 | AS2863619 free base | 99.87% | Unkown | |
| HY-119347 | Cirsilineol | Inhibitor | 98.0% | Unkown |
| HY-D0976 | NF279 | 98.5% | Unkown | |
| HY-P5425A | Tetanus Toxin (830–844) TFA | 96.13% | Unkown | |
| HY-P11303 | PADRE peptide | Ligand | 98.28% | Unkown |
| HY-P1745 | InsB (9-23) | Ligand | 98.98% | Unkown |
| HY-W060417 | iST2-1 | Inhibitor | 99.58% | Unkown |
| HY-P1065 | Apelin-36(rat, mouse) | 98.59% | Unkown | |
| HY-P6312 | ESAT6 Epitope | Ligand | 96.86% | Unkown |
| HY-P5453 | CFP10 (71–85) | 99.43% | Unkown | |
| HY-126037 | (±)-ML 209 | Antagonist | 98.14% | Unkown |
| HY-179089 | SBP-1750 | Inhibitor | 98.05% | Unkown |
| HY-W244412 | 2,5-Dioxopyrrolidin-1-yl 6-hydrazinylnicotinate hydrochloride | 95.0% | Unkown | |
| HY-107780 | Cyclic-di-GMP | Activator | 98.18% | Unkown |
| HY-105037A | Forigerimod TFA | Inhibitor | 99.88% | Unkown |
| HY-12465 | Z-Ile-Leu-aldehyde | 97.0% | Unkown | |
| HY-138115 | 7ß,27-Dihydroxycholesterol | Activator | 99.58% | Unkown |
| HY-14134 | BMS-378806 | Inhibitor | 98.94% | Unkown |
| HY-157793 | SMU-L11 | 99.64% | Unkown | |
| HY-165613 | Pam2Cys | 99.82% | Unkown | |
| HY-76648 | NBD-556 | Inhibitor | 99.57% | Unkown |
| HY-P991754 | Anti-Mouse TREM2 Antibody (178) | 98.92% | Unkown | |
| HY-100039 | YYA-021 | Inhibitor | 98.96% | Unkown |
| HY-137640A | Sp-8-Br-cAMPS sodium | Agonist | 99.9% | Unkown |
| HY-162972 | PROTAC PD-L1 degrader-2 | Degrader | 95.23% | Unkown |
| HY-171860 | FC-14369 | Inhibitor | 97.85% | Unkown |
| HY-P1409A | ADWX 1 TFA | Inhibitor | 98.37% | Unkown |
| HY-P5917A | Vm24-toxin TFA | Inhibitor | 95.47% | Unkown |
| HY-Y0781S5 | Pyruvic acid-13C,d4 | 99.80% | Unkown | |
| HY-115488A | BNM-III-170 | Inhibitor | 98.48% | Unkown |
| HY-123312 | CK-548 | Inhibitor | 90% | Unkown |
| HY-146231 | SS47 | Degrader | / | Unkown |
| HY-148432 | FGF22-IN-1 | Inhibitor | 98.07% | Unkown |
| HY-162133 | MSA-2-Pt | / | Unkown | |
| HY-P1064A | Apelin-36(human) TFA | 99.42% | Unkown | |
| HY-16106S | Talazoparib-13C,d4 | 99.31% | Unkown | |
| HY-106055 | Murabutide | / | Unkown | |
| HY-108136 | Bisindolylmaleimide X | / | Unkown | |
| HY-110382S | Cyclic-di-GMP-13C20,15N10 disodium | Activator | / | Unkown |
| HY-111366 | CD12681 | Agonist | / | Unkown |
| HY-116282W | Dextran sulfate sodium salt (MW 6500-10000) | Inhibitor | / | Unkown |
| HY-119202 | (S)-BMS-378806 | / | Unkown | |
| HY-121820 | DMJ-I-228 | Inhibitor | / | Unkown |
| HY-123902 | Ophiobolin C | Inhibitor | / | Unkown |
| HY-126675G | AS2863619 (GMP) | / | Unkown | |
| HY-131675 | CH-100 | / | Unkown | |
| HY-134809A | Cyclotriazadisulfonamide hydrochloride | Inhibitor | / | Unkown |
| HY-137618B | Rp-dGTPαS | / | Unkown | |
| HY-143712R | Allolithocholic acid (Standard) | / | Unkown | |
| HY-143712S1 | Allolithocholic Acid-d4 | / | Unkown | |
| HY-144746 | PD-1/PD-L1-IN-26 | Inhibitor | / | Unkown |
| HY-15091 | Anisperimus | / | Unkown | |
| HY-154771S | Clopidogrelat-13C,d4 | / | Unkown | |
| HY-159123 | KHK-6 | Inhibitor | / | Unkown |
| HY-161255 | 3,4-DAA | Inhibitor | / | Unkown |
| HY-169335 | HIV-1 inhibitor-77 | Inhibitor | / | Unkown |
| HY-170948 | A2AR modulator-1 | Modulator | / | Unkown |
| HY-171859 | FC-14367 | Inhibitor | / | Unkown |
| HY-171862 | Nef ligand-2 | / | Unkown | |
| HY-173000 | STAT3-IN-40 | / | Unkown | |
| HY-176273 | RORγt inverse agonist 35 | Agonist | / | Unkown |
| HY-176755 | CCL-34 | Activator | / | Unkown |
| HY-177277 | HM5023507 | Inhibitor | / | Unkown |
| HY-179734 | PROTAC BRD4 Degrader-41 | / | Unkown | |
| HY-180563 | ADC 38 drug linker | / | Unkown | |
| HY-181599 | XAN-5 | / | Unkown | |
| HY-181663 | PJ27 | Inhibitor | / | Unkown |
| HY-181673 | ICD inducer-2 | / | Unkown | |
| HY-182369 | VA06 | Inhibitor | / | Unkown |
| HY-182674 | VGD020 | Inhibitor | / | Unkown |
| HY-182802 | Ferroptosis inducer-15 | / | Unkown | |
| HY-183784 | P2X7R antagonist-1 | / | Unkown | |
| HY-186205 | (Rac)-EGC-M5 | / | Unkown | |
| HY-B0094S3 | Artemisinin-13C,d4 | / | Unkown | |
| HY-B0426AS2 | Olopatadine-d6 hydrochloride | / | Unkown | |
| HY-B1473S2 | Serotonin-13C,D4 | / | Unkown | |
| HY-D3181 | CyGbPF | / | Unkown | |
| HY-D3334 | PE-CF594 | / | Unkown | |
| HY-N17465 | Dendronobiloside D | Inhibitor | / | Unkown |
| HY-N20707 | Castalagin | / | Unkown | |
| HY-P0272A | Peptide T TFA | Inhibitor | / | Unkown |
| HY-P10308 | [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) | / | Unkown | |
| HY-P10382 | M133 peptide | / | Unkown | |
| HY-P10593 | Influenza A NP (383-391) (HLA-B27) | / | Unkown | |
| HY-P1065A | Apelin-36(rat, mouse) TFA | / | Unkown | |
| HY-P1066A | Apelin-17(human, bovine) TFA | / | Unkown | |
| HY-P10826 | PD-1/PD-L1 inhibitory peptide C8 | Inhibitor | / | Unkown |
| HY-P11090 | TpD | / | Unkown | |
| HY-P11122 | MSP-1 P2 | Activator | / | Unkown |
| HY-P11490 | DPMI-ω | Antagonist | / | Unkown |
| HY-P11802 | CD4 (81-92) (human) | Inhibitor | / | Unkown |
| HY-P2561 | Influenza Matrix Protein (61-72) | / | Unkown | |
| HY-P3554 | Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl | Inhibitor | / | Unkown |
| HY-P4015 | VIP (1-12), human, porcine, rat, ovine | Ligand | / | Unkown |
| HY-P4902 | Retrocyclin-1 | Inhibitor | / | Unkown |
| HY-P5917 | Vm24-toxin | Inhibitor | / | Unkown |
| HY-P5930 | HOXB7 8–25 | / | Unkown | |
| HY-RS02245 | CD4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W005355S8 | Sodium 2-oxobutanoate-13C,d4 | 98.0% | Unkown | |
| HY-W006057AS14 | Sodium 3-methyl-2-oxobutanoate-13C,d4 | / | Unkown | |
| HY-W062109S | Olopatadine-d6 | / | Unkown | |
| HY-W387035 | D-α-Methyl DOPA | / | Unkown | |
| HY-W654058 | L-Arginine-13C,d4 dihydrochloride | / | Unkown | |
| HY-W795993 | TJU103 | Inhibitor | / | Unkown |
| HY-107780A | Cyclic-di-GMP sodium | Activator | / | Unkown |
| HY-115488 | BNM-III-170 free base | Inhibitor | / | Unkown |
| HY-117160S2 | 4-trans-Hydroxy glibenclamide-13C,d4 | / | Unkown | |
| HY-120630 | BMS-663749 | Inhibitor | / | Unkown |
| HY-123756 | NBD-10007 | Inhibitor | / | Unkown |
| HY-12926 | ST7612AA1 | / | Unkown | |
| HY-15440AS | Fostemsavir-d8 | Inhibitor | / | Unkown |
| HY-173077 | PD-L1/LpxC-IN-1 | Inhibitor | / | Unkown |
| HY-174625 | Human IL2 mRNA | 92.6% | Unkown | |
| HY-174725 | Human CXCR4 mRNA | / | Unkown | |
| HY-174754 | Human CCL28 mRNA | / | Unkown | |
| HY-174765 | Human CCL18 mRNA | / | Unkown | |
| HY-176280 | SARS-CoV-2-IN-115 | Inhibitor | / | Unkown |
| HY-181831 | XQ2 | Activator | / | Unkown |
| HY-181841 | TLR8 agonist 10 | / | Unkown | |
| HY-182376 | JRC-I-191 | Inhibitor | / | Unkown |
| HY-182690 | CK147 | Inhibitor | / | Unkown |
| HY-B0202S4 | Irbesartan-13C,d4 | / | Unkown | |
| HY-B0426AS | Olopatadine-d3 hydrochloride | / | Unkown | |
| HY-B0757 | Vitamin E nicotinate | Inhibitor | / | Unkown |
| HY-N5178 | Chloropeptin I | Inhibitor | / | Unkown |
| HY-RS16540 | Cd4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS22972 | Cd4 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W013677S1 | 4-Fluorobenzoic acid-13C,d4 | / | Unkown | |
| HY-Y0788R | Indoline (Standard) | / | Unkown | |
| HY-110216 | 5J-4 | Inhibitor | 95% | Unkown |
Inhibitory Antibodies
(34)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990792 | Anti-Mouse CD4 Antibody (GK1.5) | Inhibitor | 99.16% | Unkown |
| HY-108831A | Natalizumab (Anti-CD49d) | Inhibitor | 99.71% | Unkown |
| HY-P990254 | Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) | Inhibitor | 99% | Unkown |
| HY-P990837 | Anti-IL-4 Antibody (MP4-25D2) | Inhibitor | ≥95.0% | Unkown |
| HY-P99141 | Anti-Mouse LAG-3 Antibody (C9B7W) | Inhibitor | 99% | Unkown |
| HY-P990839 | Anti-IFNγ Antibody (B133.5) | Inhibitor | ≥95.0% | Unkown |
| HY-P990242 | Anti-Mouse Galectin-9 Antibody (RG9-1) | Inhibitor | 95.64% | Unkown |
| HY-P99999 | Anti-Mouse CD4 Antibody (YTS 191) | Inhibitor | / | Unkown |
| HY-P991112 | Anti-Mouse CD8α Antibody (YTS169.4) | Inhibitor | 98.99% | Unkown |
| HY-P990175 | Anti-Mouse OX40L/CD134L Antibody (RM134L) | Inhibitor | 95.00% | Unkown |
| HY-P99680 | Keliximab | Inhibitor | 98.23% | Unkown |
| HY-P990861 | Anti-CD4 Antibody (OKT-4) | 95.00% | Unkown | |
| HY-P991110 | Anti-Mouse CD25 Antibody (7D4) | Inhibitor | ≥99.0% | Unkown |
| HY-P991447 | Anti-VSIR/VISTA Antibody (SG7) | Inhibitor | 98.07% | Unkown |
| HY-P992030 | FB102 | 99.17% | Unkown | |
| HY-P990249 | Anti-Mouse DR5/CD262 Antibody (MD5-1) | Inhibitor | 99.20% | Unkown |
| HY-P990264 | Anti-Mouse CD70 Antibody (FR70) | Inhibitor | 95.00% | Unkown |
| HY-P990796 | Anti-Mouse IL-2 Antibody (S4B6-1) | Inhibitor | 96.97% | Unkown |
| HY-P991479 | Amtabafusp alfa | 99% | Unkown | |
| HY-P990135 | Anti-Rat CD4 Antibody (OX-38) | Inhibitor | 95.00% | Unkown |
| HY-P990304 | Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) | Inhibitor | ≥95.0% | Unkown |
| HY-P992063 | Anti-Mouse CD8α Antibody (YTS 105.18) | / | Unkown | |
| HY-P990353 | Anti-CD4 Antibody (TRX1) | Inhibitor | 99.28% | Unkown |
| HY-P990857 | Anti-CD54/ICAM-1 Antibody (R6-5-D6) | Inhibitor | / | Unkown |
| HY-P991762 | Anti-Rat CD4 Antibody (W3/25) | Inhibitor | / | Unkown |
| HY-P991824 | Anti-Mouse CD4 Antibody (YTS 177) | Inhibitor | / | Unkown |
| HY-P991892 | IT1208 | Inhibitor | / | Unkown |
| HY-P991892A | IT1208 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P992056 | Anti-Human/Mouse LY6E Antibody (9B12) | / | Unkown | |
| HY-P992434 | OSE-279 | / | Unkown | |
| HY-P992519 | PF-06940434 | / | Unkown | |
| HY-P99495 | Cedelizumab | Inhibitor | / | Unkown |
| HY-P99790 | Priliximab | / | Unkown | |
| HY-P991318 | AR20.5 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service